LENZ Therapeutics, Inc.
NASDAQ:LENZBiotechnology
-$0.42 today
- Market cap
- $100.86M
- Beta
- 1.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.48
Volume 0.62M
Average 0.89M
LENZ Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
LENZ Therapeutics, Inc.NASDAQ: LENZ
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $44.85M rose 304.9% year over year, ahead of the +263.0% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.5% from the prior quarter. Over 3 fiscal years it compounded at +175.2% a year.
Context
- Selling, general & admin amounted to 476.0% of revenue in FY2025.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $23.83M (-73.8%) for the fiscal year ending Dec 2026, a slowdown from the +216.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $44.85M+13.5% QoQ
- Last fiscal yearDec 2025
- $90.85M+216.0% YoY
- LTMMar 2026
- $124.62M+263.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 90.85M USD
- Year-over-year change
- +216.0%
- 4-year CAGR
- +42.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.85M | +216.0% |
| FY2024 | 2024-12-31 | 28.75M | +122.4% |
| FY2023 | 2023-12-31 | 12.93M | +196.6% |
| FY2022 | 2022-12-31 | 4.36M | -80.0% |
| FY2021 | 2021-12-31 | 21.78M | — |
Selling, General & Admin vs competitors
How LENZ compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +263.0% is the 2nd highest of 11, against a peer median of +14.8%.
- Selling, general & admin amounts to 593.8% of revenue for LENZ, versus a peer median of 76.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $261.22M USD | +825.5% | +131.1% | 263.9% |
| LTM Mar 2026 | $154.66M USD | -2.5% | +54.0% | 78.9% | |
| LTM Jun 2026 | $152.74M USD | -3.6% | +9.9% | 73.2% | |
| LTM Mar 2026 | $124.62M USD | +263.0% | +175.2% | 593.8% | |
| LTM Mar 2026 | $56.47M USD | +8.0% | +20.6% | 1399.8% | |
| LTM Mar 2026 | $48.34M USD | +69.0% | +56.7% | — | |
| LTM Mar 2026 | $31.48M USD | +21.6% | +23.3% | — | |
| LTM Mar 2026 | $27.59M USD | +58.7% | +25.2% | — | |
| LTM Mar 2026 | $23.07M USD | +35.6% | +29.0% | — | |
| FY2025 | €20.22M EUR | -1.5% | +4.2% | 68.2% | |
| LTM Mar 2026 | $15.94M USD | -39.5% | -3.8% | 8.3% | |
| Peer median (excluding LENZ) | — | +14.8% | +24.2% | 76.0% | |
Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15M | 0 | 0 | 19.09M |
| Cost of Revenue | 734K | 0 | 0 | 58K | 705K |
| Gross Profit | (734K) | 15M | 0 | (58K) | 18.38M |
| Gross Margin | — | 100.0% | — | — | 96.3% |
| Research & Development | 37.93M | 21.13M | 59.5M | 29.8M | 18.67M |
| Selling, General & Admin | 21.78M | 4.36M | 12.93M | 28.75M | 90.85M |
| Operating Expenses | 59.71M | 25.48M | 72.43M | 58.55M | 109.52M |
| Depreciation & Amortization | 734K | 8K | 15K | 58K | 287K |
| EBITDA | (70.03M) | (10.46M) | (70.13M) | (49.71M) | (81.34M) |
| EBITDA Margin | — | -69.7% | — | — | -426.1% |
| Operating Income | (60.44M) | (10.48M) | (72.43M) | (58.61M) | (91.14M) |
| Operating Margin | — | -69.9% | — | — | -477.5% |
| Interest Income | 0 | 0 | 2.19M | 8.55M | 9.76M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (10.32M) | 19K | 2.28M | 8.84M | 9.51M |
| Income Before Tax | (70.76M) | (10.46M) | (70.15M) | (49.77M) | (81.63M) |
| Pre-Tax Margin | — | -69.8% | — | — | -427.6% |
| Income Tax Expense | 0 | 347K | (179K) | 1K | 502K |
| Net Income | (70.76M) | (10.81M) | (69.97M) | (49.77M) | (82.13M) |
| Net Margin | — | -72.1% | — | — | -430.3% |
| EPS (Basic) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| EPS (Diluted) | (8.54) | (12.89) | (15.30) | (2.34) | (2.85) |
| Weighted Avg Shares | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
| Weighted Avg Shares (Diluted) | 8.29M | 7.84M | 8.15M | 21.28M | 28.81M |
LENZ Therapeutics, Inc.
NASDAQ:LENZ
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.